Initial experiments were performed using donor adrenal tissue from young (5-7 week old) rats, and showed reduced apomorphine-induced rotation in SN lesioned rats25. Histochemistry showed intense staining for catecholamines around the graft sites. Some of the transplanted cells were elongated and produced fine fibres, but these were found almost entirely within the grafts and rarely penetrated the caudate nucleus, suggesting that catecholamines or other substances diffused from the grafts to the receptor sites in the caudate rather than forming specific neuronal connections.
If adrenal medulla autografts are to be applied clinically to Parkinson's disease, the host, and thus the donor tissue, is elderly. Further experiments using fully mature or ageing rat adrenal medulla grafts have thus been performed'0. Neither tissue from 1-or 2-year-old donors had any effect whatsoever on apomorphine-induced rotation. Interestingly, the morphological features of the grafts from mature donors, as shown histochemically, were indistinguishable from grafts obtained from young rats.
The use of autografts in a 50-year-old human is most closely analogous to the use of 1-year-old donor tissue in rats. Considering the above experiments in rodents, it is perhaps not surprising that adrenal autografts in middle-aged humans have met with only partial success. The adrenal medulla contains many biogenic amines and peptides and thus is highly nonspecific. Presumably future workers will consider manipulating such peripheral sources to select out purely dopaminergic cell lines.
Cell culture techniques could also be used to generate donor tissue. Human neuroblastoma cell lines which synthesize acetylcholine, noradrenaline, adrenaline, dopamine and serotonin have been characterized26. When induced to cease mitotic activity and mature, neuroblastoma cells assume a neuronal phenotype and send out axon-like processes which are capable of forming electrically active synapses27'28. If and when a neuroblastoma line is identified which has desirable characteristics for transplantation, large numbers of cells could be grown in culture and used in potentially thousands of patients with, for example, Parkinson's disease.
Although raising profound ethical issues, the possibility of cross-species transplantation might also be considered, given that the CNS seems to be at least partially immunologically privileged. Mouse SN has been successfully grafted into rats29; interventricular grafts do survive and function across major histocompatibility complex differences in rats'0. The Even considering the small numbers of animals involved, the fact that this was the first time that transplantation to primates had been tried, and that success undoubtedly depends on innumerable technical factors, these experiments show that caution should be used when applying transplantation results from rats directly to humans. It is clear that the factors influencing transplant growth, survival, cellular transformation and reinnervation will require extensive elaboration. Unless the number of surviving graft cells can be substantially increased, the limited cell survival and the small degree of morphologic transformation may be a significant impediment to primate CNS repair by transplantation. Some workers have recently begun brain grafting in marmosets, and the results are eagerly awaited.
Clinical applications So what then are the possibilities for clinical application of brain transplantation? As discussed above, much ofthe experimental work has focused on the SN and animal models of Parkinson's disease. Present drug therapy for this condition with levodopa is not ideal, especially in the long term. Central nervous system grafts could potentially offer a more physiological solution.
The effectiveness of such an approach will depend on the resolution of several issues relating to the aetiology of the disease itself and to the practical techniques to be used in human patients. The causative agent of Parkinson's disease is unidentified. If that agent is already established in the patient's system, any replacement graft becomes equally susceptible to assault. Both the viral postencephalitic form ofthe disease and the recent discovery ofMPTPinduced parkinsonism in humans31 and monkeys32
suggest that the causative agent may be external. Whether this is true of the idiopathic form of the disease and, if so, whether the external agent acts chronically once the patient is affected, remains unknown. A second aetiological factor that remains unresolved is whether the widespread neuronal degeneration seen in later stages of the disease process is secondary to or independent of the primary dopaminergic loss. If these processes are indeed secondary, then transplantation-derived replacement of dopamine neurons would be appropriate, but at an earlier stage in the disease, rather than end-stage, for which it has thus far been considered3 .
Many practical features will have to be resolved. The pattern of graft replacement is a critical feature for functional recovery, and given the size of the forebrain dopamine terminal areas in primates and humans, a large number of small grafts in different locations may be required to achieve an adequate functional compensation. In Backlund's clinical experiments1, the transplantation was to the caudate nucleus. It seems that transplantation to the putamen would be more appropriate, as the primary disorder is one of movement, and further work using this site is in progress.
A further application may be in the treatment of Alzheimer's disease. Post-mortem brains of patients with this condition show reduced cerebral cortical choline acetyltransferase and acetylcholine34'35.
These biochemical deficits are thought to reflect degenerative changes occurring in the cortical projection neurons of the forebrain nucleus basalis magnocellularis36. The memory deficit characteristic of Alzheimer's disease has been attributed to this loss, although involvement of other neurotransmitters cannot be excluded37. Clinical trials with choline precursors have been unsatisfactory38. As mentioned above, transplanted embryonic neurons can reinnervate rat brain to restore memory deficits caused by lesions of certain cortical projection neurons. Clearly much more work is required before the clinical significance of these observations is apparent.
Considering the potential for reinnervation after injury, others have transplanted CNS tissue into the spinal cord. Embryonic brainstem tissue has been successfully grafted into the partially sectioned spinal cord of adult rats39. The transplants survive, grow, differentiate and establish anatomical integration with the host cord. Use of other types of neural tissue or transplantation of tissues into intact or completely severed cords has not been successful. It is of interest that the transplants seem to prevent neuroglial scar formation'0. The potential clinical applications for grafting into the spinal cord to reverse the effects of injury are immense. Like the other applications, however, much work is still required to assess the feasibility of this.
Ethical considerations
Even if the answer to the question 'Could nerve cell transplantation have clinical application?' is yes, the question that must then be addressed is 'Should these experiments have a clinical application?' Is there a moral distinction, for example, between fetal pancreatic transplantation and fetal brain tissue transplantation? Is enough yet known about transplantation in primates to proceed to human trials? Are Backlund's 'therapeutic trials' ethical? The use of cultured cells or of adult PNS donor tissue obtained by patient consent would avoid many of the moral issues implicit in using fetal tissue. Crossspecies transplantation has been successful in rodents; similar cross-species grafting into humans raises profound ethical questions.
Conclusions
There is still much laboratory investigation to be done before further human studies can, and should, be pursued. No clinical research has as yet concerned neuronal regeneration, which has proved far superior to the replacement of deficient transmitters in animal work. The optimal time for transplantation must be determined. The optimal conditions for survival of the transplanted tissue must be identified. More specific behavioural effects of graft function in animals must be measured.
Until now, attempts at treating neurological diseases have consisted ofalleviating specific symptoms. As discussed here, it is no longer without the bounds of reality to consider that brain transplantation may be a feasible clinical approach, offering the chance of influencing the underlying pathophysiology and eventually hopefully reversing the disease process itself.
Finally, and crucially, a method of obtaining the donor tissue within the necessary ethical and legal boundaries must evolve. Medical technology should be the servant, and not dictator, of medical practice.
